MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Minnetronix Sheds Solitary Supplier Title for OEM Status

Image courtesy of Minnetronix Medical minnetronix port.jpg
The company announced the development of its own device, MindsEye, to help satisfy unmet needs in the neurosurgical market.

Minnetronix Medical, known as a contract supplier for medical devices, is now diving into developing its own products. Its first product, MindsEye, was conceptualized, developed, FDA-cleared, and manufactured internally and is now fully commercialized and available into the neurosurgery market.

MindsEye, according to the company, is the only expandable brain access port on the market. Its design allows for increased visibility, safety, and control when removing lesions deep in the brain. The access port contains a durable, compliant sheath to help better isolate lesions and support an endoscope, exoscope, or microscope, while an adjustable working channel with distal flare helps reach lesions deep in the brain. Additionally, the port uses anti-reflective sheath material to avoid distractions, see tissue clearly, and keep focus on the task at hand.

Minnetronix noted that it used its 25 years of med device partner experience to identify unmet needs in the neurosurgical market, resulting in its own market-ready products for sale and distribution.

“Minnetronix is taking partnerships in the med device industry to a whole new level, which sets us apart from contract developers and manufacturers,” said Matt Adams, vice president and general manager at Minnetronix. “Our first from-scratch product showcases our end-to-end capabilities to support our customers’ needs across device conceptualization and design, clinical research and partnerships, regulatory navigation, and manufacturing. We offer a whole new way for med device companies, startups, and investors to reduce the cost, risk, and time of building products themselves.”

The minimally invasive port can be used during surgical treatment of stroke, cancer, and other conditions and is currently successfully being used at Tulane University by Art Wang, MD, and Johnny Delashaw, MD.

“Its benefits to neurosurgeons, such as expandability, easier insertion and removal, and transparency that minimizes glare and allows surgeons to see surrounding tissue, are truly unique,” said Delashaw, a neurosurgeon and neurology professor at Tulane. “The MindsEye expandable port has raised the bar for standard of care in neurosurgery and will improve patient outcomes.”

Mizuho America will be distributing the MindsEye port in the United States.

“Mizuho’s mission is to deliver the best devices to neurosurgeons,” said William Delaney, vice president of sales at Mizuho America. “We now consider Minnetronix a partner for new device ideas and finished products. Since they handled all the steps in creating the MindsEye expandable port, we can concentrate on bringing it to market by leveraging the strength of our distribution channel to accelerate adoption and enhance patient outcomes.”

In the press release announcing the port, Minnetronix also highlighted that it had garnered four major industry awards for MindsEye’s unique technology and design.

TAGS: Technologies
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.